Benchmark indices ended a volatile session with strong gains on Wednesday after the Reserve Bank of India announced measures to tackle the rising second wave of COVID-19 pandemic. The Nifty managed to close above the 14,600 mark. Barring the Nifty Realty index, all sectoral indices on the NSE ended in the green.
As per the provisional closing data, the S&P BSE Sensex, rallied 424.04 points or 0.88% to 48,677.82. The Nifty 50 index gained 121.35 points or 0.84% to 14,617.40.
In the broader market, the S&P BSE Mid-Cap index added 1.05% while the S&P BSE Small-Cap index surged 0.77%.
The market breadth was strong. On the BSE, 1,842 shares rose and 1,097 shares fell. A total of 173 shares were unchanged.
The drug maker received a final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) for dorzolamide hydrochloride and timolol maleate ophthalmic solution.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Cosopt Ophthalmic Solution, 2% and 0.5% of Akorn Operating Company.
Dorzolamide hydrochloride and timolol maleate ophthalmic solution is a combination of dorzolamide hydrochloride carbonic anhydrase inhibitor, and timolol maleate, a beta-adrenergic receptor blocking agent, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers.
As per IQVIA, dorzolamide hydrochloride and tirnolol maleate ophthalmic solution USP, 2% and 0.5% has an estimated market size of $80 million for twelve months ending December 2020.